

Saving sight sooner makes brighter futures





Time indoors can be fun, but more time indoors is leading to a rapid escalation in myopia cases

Our eyesight is vital to learning and negotiating the world and largely impacts our potential to live full and productive lives.

When our child is diagnosed with myopia, it is vital to reduce its progress early on. The sooner it is controlled, the better our chances of maintaining long-term sight and quality of life into adulthood. However, while a range of myopia treatments exist, some can be invasive and therefore not viable for children, especially the very young. This may leave limited options for your child and their physician.

At Eyerising International, we see a world where myopia is controlled early, easily, and effectively to have a life-changing impact.



World-class technology developed by global leaders in ophthalmology

Eyerising International is an Australian-based MedTech company developing life-impacting eye-health technology to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers, and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.



Repeated Low-Level Red-Light Myopia therapy at home

Eyerising International's commitment to leading the fight against childhood myopia led to the development of our patented Repeated Low-Level Red-Light (RLRL) therapy, a highly effective and child-friendly way to slow the progression of myopia.



Designed to be easy to use at home, the device is non-invasive; can be used without additional medications, eyedrops, or contact lenses; is free of any known significant side effects; and is suitable for use by children as young as 3 and up to 16.

Simple as 3, 2, 5

Therapy involves looking into the device for 3 minutes treatment, 2 times per day, 5 days per week, with a minimum of 4 hours between sessions.


The device is controlled with a simple touchscreen and tracks each child's use.

It can also be monitored by the treating doctor

by the treating doctor and programmed to send SMS reminders to patient's guardian.

How RLRL works


In a normal eye, light passes through the lens with the focal point correctly reaching the retina.



Focal point correctly reaching retina


As myopia progresses, axial lengthening and focal point mis-alignment increase.

Continued axial lengthening and focal point misalignment leads to high myopia.



Focal point not reaching retina

The device delivers RLRL therapy to the retina.



Blood flow is stimulated to help slow the axial length's further elongation and control myopia's progression.

Clinically tested for trusted results

The Eyerising Myopia Management Device has been proven in published clinical trials to be effective in the treatment of myopia, slowing its progression by up to 87.7%.

RLRL therapy's efficacy and safety has been validated through a comprehensive ongoing clinical trial program. The results, published in leading peer-reviewed scientific publications show that with >75% compliance, exposure to RLRL therapy can control the progression of myopia.¹









No drugs, No injections, No lenses, No known significant side-effects

International approvals & regulatory status

The Eyerising Myopia Management Device meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia. It has been cleared as a medical device by the following regulators: CE (EU), TGA (AU), Medsafe (NZ), and MHRA (UK), with other regulatory clearances expected imminently. Eyerising International is ISO 13485:2016 certified by notified body BSI.

References:

 Jiang, Yu, et al. "Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial." Ophthalmology 129.5 (2022): 509-519.



To find out more about the Eyerising Myopia Management Device world-changing myopia therapy at home, get in touch with our team.

info@eyerisinginternational.com www.eyerisinginternational.com

Head Office: Suite 2.05, 9-11 Claremont St. South Yarra, Victoria 3141, Australia